BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7784940)

  • 1. [Treatment with fludarabine of chronic refractory lymphoid leukemia].
    Herrero M; Cabrera JR; Briz M; Forés R; Díez JL; Regidor C; Sanjuán I; Fernández MN
    Sangre (Barc); 1995 Apr; 40(2):115-9. PubMed ID: 7784940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
    O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
    N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
    Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
    Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
    Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fludarabine treatment of chronic lymphoid leukemia].
    Gabeeva NG; Pivnik AV; Moiseeva TN; Zybunova EE; Samoĭlova RS; Kremenetskaia AM; Varlamova EIu; Kaplanskaia IB
    Ter Arkh; 2000; 72(8):42-5. PubMed ID: 11019427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F; Lehoczky D; Demeter J
    Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
    Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
    De Rossi G; Mauro FR; Caruso R; Monarca B; Mandelli F
    Haematologica; 1993; 78(3):167-71. PubMed ID: 8375746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity.
    Spriano M; Clavio M; Carrara P; Canepa L; Miglino M; Pierri I; Celesti L; Rossi E; Vimercati R; Bruni R
    Haematologica; 1994; 79(3):218-24. PubMed ID: 7926970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
    Juliusson G; Elmhorn-Rosenborg A; Liliemark J
    N Engl J Med; 1992 Oct; 327(15):1056-61. PubMed ID: 1355853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.